Simiczyjew, A.; Dratkiewicz, E.; Van Troys, M.; Ampe, C.; Styczeń, I.; Nowak, D.
Combination of EGFR Inhibitor Lapatinib and MET Inhibitor Foretinib Inhibits Migration of Triple Negative Breast Cancer Cell Lines. Cancers 2018, 10, 335.
https://doi.org/10.3390/cancers10090335
AMA Style
Simiczyjew A, Dratkiewicz E, Van Troys M, Ampe C, Styczeń I, Nowak D.
Combination of EGFR Inhibitor Lapatinib and MET Inhibitor Foretinib Inhibits Migration of Triple Negative Breast Cancer Cell Lines. Cancers. 2018; 10(9):335.
https://doi.org/10.3390/cancers10090335
Chicago/Turabian Style
Simiczyjew, Aleksandra, Ewelina Dratkiewicz, Marleen Van Troys, Christophe Ampe, Ilona Styczeń, and Dorota Nowak.
2018. "Combination of EGFR Inhibitor Lapatinib and MET Inhibitor Foretinib Inhibits Migration of Triple Negative Breast Cancer Cell Lines" Cancers 10, no. 9: 335.
https://doi.org/10.3390/cancers10090335
APA Style
Simiczyjew, A., Dratkiewicz, E., Van Troys, M., Ampe, C., Styczeń, I., & Nowak, D.
(2018). Combination of EGFR Inhibitor Lapatinib and MET Inhibitor Foretinib Inhibits Migration of Triple Negative Breast Cancer Cell Lines. Cancers, 10(9), 335.
https://doi.org/10.3390/cancers10090335